NCT01915212View on ClinicalTrials.gov

Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

September 26, 2013

Primary Completion Date

March 6, 2017

Study Completion Date

March 6, 2017

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

HSV529

The vaccine was administered intramuscularly (deltoid muscle) as a 0.5 mL solution containing 1 x 10(7) plaque forming units on day 0, one month after the first dose (day 30) and then six months after the first dose (day 180).

OTHER

Placebo

Sodium Chloride 0.9%

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
collaborator

Sanofi Pasteur, a Sanofi Company

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01915212 - Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection | Biotech Hunter | Biotech Hunter